Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.
暂无分享，去创建一个
D. Siegel | D. Reece | G. Schiller | M. Sebag | N. Bahlis | C. Seet | K. Song | J. Matous | B. Anz | S. Ganguly | C. Samaras | G. Talamo | J. Berdeja | S. Srinivas | F. Zafar | D. Quick | M. Bar | M. Acosta-Rivera | Weiyuan Chung | G. Fonseca